# Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"

> **NCT02139592** · — · COMPLETED · sponsor: **Takeda** · enrollment: 292 (actual)

## Conditions studied

- Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma

## Interventions

- **DRUG:** Brentuximab vedotin (recombinant)

## Key facts

- **NCT ID:** NCT02139592
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-17
- **Primary completion:** 2017-06-30
- **Final completion:** 2017-06-30
- **Target enrollment:** 292 (ACTUAL)
- **Last updated:** 2020-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02139592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02139592, "Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02139592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*